Taysha Gene Therapies shareholders approve authorized share increase to 700M

Taysha Gene Therapies, Inc.

Authorized common stock increased from 400M to 700M shares; approved 171.3M for, 8.2M against.
Directors Phillip B. Donenberg and Sukumar Nagendran elected with 114.3M and 123.3M votes for, respectively.
Deloitte & Touche ratified as independent auditor for FY2025; 179.4M votes for.
Annual meeting turnout: 179.6M shares (~87%) of 205.1M outstanding represented.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Taysha Gene Therapies, Inc.: Increase in authorized common stock from 400,000,000 to 700,000,000 (effective 2025-06-02).

Change: charter amendment
Effective: 2025-06-02

Exact text from the filing

At the Annual Meeting, the Company’s stockholders approved an amendment to the Company’s Amended and Restated Certificate of Incorporation (the “ Amendment ”) to increase the authorized number of shares of common stock from 400,000,000 to 700,000,000.

View on SEC.gov

Browse all governance changes →

Taysha Gene Therapies, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-25-133745

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.